Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been given a consensus rating of “Hold” by the twenty research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $73.83.
Several research analysts have recently issued reports on INCY shares. JPMorgan Chase & Co. increased their price objective on shares of Incyte from $59.00 to $61.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. JMP Securities reaffirmed a “market perform” rating on shares of Incyte in a research note on Tuesday, September 17th. Deutsche Bank Aktiengesellschaft boosted their price objective on Incyte from $55.00 to $60.00 and gave the stock a “hold” rating in a research note on Thursday, August 1st. William Blair restated an “outperform” rating on shares of Incyte in a report on Monday, September 9th. Finally, Truist Financial reaffirmed a “hold” rating and set a $74.00 target price (down from $83.00) on shares of Incyte in a report on Wednesday, September 18th.
Get Our Latest Analysis on Incyte
Insiders Place Their Bets
Institutional Trading of Incyte
Hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its position in Incyte by 48.8% in the 4th quarter. Wellington Management Group LLP now owns 131,649 shares of the biopharmaceutical company’s stock valued at $8,266,000 after acquiring an additional 43,160 shares during the period. Fulton Bank N.A. bought a new position in Incyte during the 1st quarter worth $1,425,000. FORVIS Wealth Advisors LLC acquired a new position in Incyte during the 1st quarter worth about $1,495,000. ProShare Advisors LLC grew its position in shares of Incyte by 14.4% in the 1st quarter. ProShare Advisors LLC now owns 63,086 shares of the biopharmaceutical company’s stock valued at $3,594,000 after buying an additional 7,925 shares during the last quarter. Finally, Kennedy Capital Management LLC acquired a new stake in shares of Incyte in the first quarter valued at about $463,000. Institutional investors and hedge funds own 96.97% of the company’s stock.
Incyte Stock Performance
Incyte stock opened at $67.49 on Friday. Incyte has a 52 week low of $50.27 and a 52 week high of $70.36. The company has a current ratio of 1.92, a quick ratio of 1.84 and a debt-to-equity ratio of 0.01. The stock has a market cap of $15.15 billion, a P/E ratio of 20.45, a price-to-earnings-growth ratio of 5.17 and a beta of 0.73. The stock has a 50 day moving average of $64.33 and a 200-day moving average of $60.26.
Incyte (NASDAQ:INCY – Get Free Report) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($2.60). The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.01 billion. Incyte had a net margin of 2.52% and a return on equity of 0.75%. Incyte’s revenue was up 9.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.77 earnings per share. On average, analysts expect that Incyte will post 0.66 EPS for the current fiscal year.
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Further Reading
- Five stocks we like better than Incyte
- What is a Death Cross in Stocks?
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What is the FTSE 100 index?
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.